RecruitingPhase 4ACTRN12611001093976

The neuroendocrine and metabolic effects of oestrogens

The neuroendocrine and metabolic effects of oestrogens in healthy postmenopausal women and men the same age

Sponsor

Garvan Institute of Medical Research

Enrollment

20 participants

Start Date

Aug 3, 2010

Study Type

Interventional

Conditions

Metabolic effects of oestrogens Neuroendocrine regulation of GH secretion by oestrogens

Summary

The purpose of this study is to understand how oestrogen controls the use of fat in the liver. The hypothesis is that oestrogen is required to prevent the accumulation of fat in the liver. The mechanism may be direct or mediated by other hormones such as growth hormone, which is regulated by oestrogen. We wish to study the effects of oestrogen compounds called Selective Oestrogen Receptor Modulators (tamoxifen) and a drug that prevents oestrogen production (letrozole) on the secretion of growth hormone from the special gland in brain and how they control the liver production and burning of fat in men and women. We wish to compare these effects with that of natural oestrogen itself in women.

Eligibility

Sex: Both males and femalesMin Age: 50 YearssMax Age: 70 Yearss

Plain Language Summary

Simplified for easier understanding

This study is looking at how the hormone oestrogen affects fat metabolism in the liver and how growth hormone secretion is involved. Researchers will study the effects of oestrogen-modifying drugs (tamoxifen and letrozole) in healthy postmenopausal women and men of a similar age. Understanding these relationships may help explain conditions like fatty liver disease. You may be eligible if: - You are a healthy postmenopausal woman or a man in the same age range (50 to 70 years old) - Your BMI is below 25 kg/m² You may NOT be eligible if: - You have liver disease, kidney disease, cancer, diabetes, or a hormonal disorder - You have any condition likely to affect how the study medications are processed by your body Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

1) Oestradiol 2 mg once daily orally for 2 weeks, followed by 4 weeks washout; 2) tamoxifen 20 mg once daily orally for 2 weeks, followed by 4 weeks washout; 3) letrozole 5 mg once daily orally for

1) Oestradiol 2 mg once daily orally for 2 weeks, followed by 4 weeks washout; 2) tamoxifen 20 mg once daily orally for 2 weeks, followed by 4 weeks washout; 3) letrozole 5 mg once daily orally for 2 weeks Women take all 3 treatments, men take only tamoxifen and letrozole.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611001093976